XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -3.36%64.81B | -5.01%16.22B | -4.19%16.11B | -3.63%16.69B | -0.40%15.8B | 12.84%67.06B | 2.85%17.07B | 12.11%16.81B | 21.56%17.32B | 16.73%15.86B |
Operating revenue | -3.36%64.81B | -5.01%16.22B | -4.19%16.11B | -3.63%16.69B | -0.40%15.8B | 12.84%67.06B | 2.85%17.07B | 12.11%16.81B | 21.56%17.32B | 16.73%15.86B |
Cost of revenue | -5.28%41.49B | -5.71%10.66B | -4.24%10.4B | -7.48%10.46B | -3.49%9.96B | 4.49%43.8B | -4.22%11.3B | 4.93%10.86B | 12.04%11.31B | 6.78%10.32B |
Gross profit | 0.26%23.32B | -3.64%5.56B | -4.09%5.7B | 3.61%6.23B | 5.36%5.84B | 32.84%23.26B | 20.25%5.77B | 28.14%5.95B | 44.70%6.01B | 41.23%5.54B |
Operating expense | -0.44%10.25B | 0.00%2.63B | 2.36%2.56B | 16.43%2.74B | -17.47%2.32B | 18.59%10.3B | 20.18%2.63B | 12.73%2.5B | 6.70%2.36B | 35.86%2.81B |
Selling and administrative expenses | 4.65%6.67B | 0.74%1.77B | 2.77%1.67B | 8.12%1.65B | 7.79%1.58B | 12.74%6.37B | 18.73%1.76B | 15.92%1.62B | 7.23%1.53B | 8.69%1.46B |
Research and development costs | -0.05%2.11B | -6.32%519M | -3.79%533M | 1.33%535M | 10.17%520M | 16.21%2.11B | 38.15%554M | 16.39%554M | 10.00%528M | 3.28%472M |
Other operating expenses | -18.70%1.48B | 6.83%344M | 10.94%355M | 85.33%556M | -74.54%223M | 49.26%1.82B | 3.87%322M | -5.60%320M | -0.99%300M | 229.32%876M |
Operating profit | 0.82%13.07B | -6.70%2.92B | -8.76%3.15B | -4.65%3.48B | 28.85%3.52B | 46.86%12.97B | 20.31%3.13B | 42.23%3.45B | 87.86%3.65B | 47.22%2.73B |
Net non-operating interest income expense | -2,911.76%-512M | -343.18%-107M | -383.33%-17M | 38.71%-19M | 80.56%-7M | 93.84%-17M | 191.67%44M | 110.53%6M | 62.65%-31M | 59.09%-36M |
Non-operating interest income | ---- | ---- | -20.00%108M | 22.92%118M | 46.24%136M | 195.81%494M | 146.38%170M | 159.62%135M | 284.00%96M | 342.86%93M |
Non-operating interest expense | 0.20%512M | -15.08%107M | -3.10%125M | 7.87%137M | 10.85%143M | 15.35%511M | 7.69%126M | 18.35%129M | 17.59%127M | 18.35%129M |
Other net income (expense) | 704.95%813M | 500.00%426M | -153.33%-32M | 19.35%37M | 132.79%20M | -49.25%101M | 115.50%71M | -68.42%60M | -86.81%31M | -126.29%-61M |
Gain on sale of security | ---- | ---- | -556.52%-105M | -60.00%12M | 171.08%59M | -277.08%-85M | 81.54%-55M | -82.84%23M | -83.05%30M | -337.14%-83M |
Special income (charges) | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
-Less:Impairment of capital assets | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | 337.10%813M | 238.10%426M | 97.30%73M | 2,400.00%25M | -277.27%-39M | -82.71%186M | -83.53%126M | -33.93%37M | -98.28%1M | -88.83%22M |
Income before tax | 2.48%13.37B | -0.18%3.24B | -11.86%3.1B | -4.16%3.5B | 34.09%3.53B | 49.11%13.05B | 54.79%3.25B | 37.41%3.52B | 74.24%3.65B | 31.77%2.63B |
Income tax | -5.47%2.63B | -21.12%463M | -12.53%642M | 11.17%836M | -2.82%688M | 34.54%2.78B | -8.85%587M | 39.28%734M | 76.11%752M | 50.96%708M |
Earnings from equity interest net of tax | -30.16%44M | -9.09%10M | -41.67%7M | -29.17%17M | -37.50%10M | 231.58%63M | 1,200.00%11M | 33.33%12M | 500.00%24M | 128.57%16M |
Net income | 4.41%10.79B | 4.38%2.79B | -11.82%2.46B | -8.31%2.68B | 46.96%2.85B | 54.12%10.33B | 83.84%2.67B | 36.91%2.79B | 74.78%2.92B | 26.35%1.94B |
Net income continuous Operations | 4.41%10.79B | 4.38%2.79B | -11.82%2.46B | -8.31%2.68B | 46.96%2.85B | 54.12%10.33B | 83.84%2.67B | 36.91%2.79B | 74.78%2.92B | 26.35%1.94B |
Minority interest income | -33.33%-4M | 66.67%-1M | 0.00%-1M | 0 | -100.00%-2M | -200.00%-3M | -3M | 0.00%-1M | 2M | -1M |
Net income attributable to the parent company | 4.42%10.79B | 4.30%2.79B | -11.81%2.46B | -8.25%2.68B | 46.99%2.86B | 54.14%10.34B | 84.04%2.68B | 36.89%2.79B | 74.66%2.92B | 26.42%1.94B |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 4.42%10.79B | 4.30%2.79B | -11.81%2.46B | -8.25%2.68B | 46.99%2.86B | 54.14%10.34B | 84.04%2.68B | 36.89%2.79B | 74.66%2.92B | 26.42%1.94B |
Basic earnings per share | 9.54%22.17 | 9.42%5.81 | -7.12%5.09 | -3.51%5.5 | 53.72%5.78 | 59.12%20.24 | 88.97%5.31 | 40.87%5.48 | 80.95%5.7 | 30.56%3.76 |
Diluted earnings per share | 9.59%22.05 | 9.47%5.78 | -7.16%5.06 | -3.35%5.48 | 53.74%5.75 | 59.18%20.12 | 89.25%5.28 | 40.83%5.45 | 81.15%5.67 | 30.77%3.74 |
Dividend per share | 8.40%5.42 | 8.46%1.41 | 8.46%1.41 | 8.33%1.3 | 8.33%1.3 | 8.23%5 | 8.33%1.3 | 8.33%1.3 | 8.11%1.2 | 8.11%1.2 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |